High fat diet induced diabetic cardiomyopathy

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 85, Issue 5, 2011, Pages 219-225

  Dirkx, Ellen ^a   Schwenk, Robert W ^a   Glatz, Jan F C ^a   Luiken, Joost J F P ^a   van Eys, Guillaume J J M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; CERAMIDE; DIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE;

ARTICLE; CARDIOMEGALY; DIABETIC CARDIOMYOPATHY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; FATTY ACID ANALYSIS; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; HEART MUSCLE CONTRACTILITY; HUMAN; HYPERLIPIDEMIA; LIPID DIET; LIPID STORAGE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD36; CELL MEMBRANE; CERAMIDES; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DIETARY FATS; DIGLYCERIDES; FATTY ACIDS; HUMANS; MITOCHONDRIA, HEART; MYOCARDIUM; OXIDATION-REDUCTION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; REACTIVE OXYGEN SPECIES;

EID: 80053604536     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2011.04.018     Document Type: Article

References (94)

1. Wentz A.E., d'Avignon D.A., Weber M.L., et al. Adaptation of myocardial substrate metabolism to a ketogenic nutrient environment. J. Biol. Chem. 2010, 285:24447-24456.
2. Scolletta S., Biagioli B. Energetic myocardial metabolism and oxidative stress: let's make them our friends in the fight against heart failure. Biomed. Pharmacother. 2010, 64:203-207.
3. Carley A.N., Severson D.L. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim. Biophys. Acta 2005, 1734:112-126.
4. Devereux R.B., Roman M.J., Paranicas M., et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000, 101:2271-2276.
5. Galderisi M., Anderson K.M., Wilson P.W., Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham heart study). Am. J. Cardiol. 1991, 68:85-89.
6. Taha M., Lopaschuk G.D. Alterations in energy metabolism in cardiomyopathies. Ann. Med. 2007, 39:594-607.
7. Luiken J.J., Turcotte L.P., Bonen A. Protein-mediated palmitate uptake and expression of fatty acid transport proteins in heart giant vesicles. J. Lipid Res. 1999, 40:1007-1016.
8. Tao N., Wagner S.J., Lublin D.M. CD36 is palmitoylated on both N- and C-terminal cytoplasmic tails. J. Biol. Chem. 1996, 271:22315-22320.
9. Glatz J.F., Luiken J.J., Bonen A. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol. Rev. 2010, 90:367-417.
10. Bonen A., Han X.X., Habets D.D., Febbraio M., Glatz J.F., Luiken J.J. A null mutation in skeletal muscle FAT/CD36 reveals its essential role in insulin- and AICAR-stimulated fatty acid metabolism. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E1740-E1749.
11. Koonen D.P., Febbraio M., Bonnet S., et al. CD36 expression contributes to age-induced cardiomyopathy in mice. Circulation 2007, 116:2139-2147.
12. Kuang M., Febbraio M., Wagg C., Lopaschuk G.D., Dyck J.R. Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation 2004, 109:1550-1557.
13. Garcia-Martinez C., Marotta M., Moore-Carrasco R., et al. Impact on fatty acid metabolism and differential localization of FATP1 and FAT/CD36 proteins delivered in cultured human muscle cells. Am. J. Physiol. Cell Physiol. 2005, 288:C1264-C1272.
14. Bell J.A., Reed M.A., Consitt L.A., et al. Lipid partitioning, incomplete fatty acid oxidation, and insulin signal transduction in primary human muscle cells: effects of severe obesity, fatty acid incubation, and fatty acid translocase/CD36 overexpression. J. Clin. Endocrinol. Metab. 2010, 95:3400-3410.
15. Hirano K., Kuwasako T., Nakagawa-Toyama Y., Janabi M., Yamashita S., Matsuzawa Y. Pathophysiology of human genetic CD36 deficiency. Trends Cardiovasc. Med. 2003, 13:136-141.
16. Schwenk R.W., Dirkx E., Coumans W.A., et al. Requirement for distinct vesicle-associated membrane proteins in insulin- and AMP-activated protein kinase (AMPK)-induced translocation of GLUT4 and CD36 in cultured cardiomyocytes. Diabetologia 2010, 53:2209-2219.
17. Normann P.T., Norseth J., Flatmark T. Acyl-CoA synthetase activity of rat heart mitochondria. Substrate specificity with special reference to very-long-chain and isomeric fatty acids. Biochim. Biophys. Acta 1983, 752:474-481.
18. Woldegiorgis G., Shi J., Zhu H., Arvidson D.N. Functional characterization of mammalian mitochondrial carnitine palmitoyltransferases I and II expressed in the yeast Pichia pastoris. J. Nutr. 2000, 130:310S-314S.
19. de Vries Y., Arvidson D.N., Waterham H.R., Cregg J.M., Woldegiorgis G. Functional characterization of mitochondrial carnitine palmitoyltransferases I and II expressed in the yeast Pichia pastoris. Biochemistry 1997, 36:5285-5292.
20. Kudo N., Barr A.J., Barr R.L., Desai S., Lopaschuk G.D. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J. Biol. Chem. 1995, 270:17513-17520.
21. Sato Y., Okajima F., Oikawa S. Therapeutic points and meaning of dyslipidemia in diabetic patients. Nippon Rinsho 2010, 68:905-910.
22. Boudina S., Abel E.D. Diabetic cardiomyopathy revisited. Circulation 2007, 115:3213-3223.
23. Banke N.H., Wende A.R., Leone T.C., et al. Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARalpha. Circ. Res. 2010, 107:233-241.
24. Olson M.S., Dennis S.C., DeBuysere M.S., Padma A. The regulation of pyruvate dehydrogenase in the isolated perfused rat heart. J. Biol. Chem. 1978, 253:7369-7375.
25. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294:1866-1870.
26. Huss J.M., Kelly D.P. Nuclear receptor signaling and cardiac energetics. Circ. Res. 2004, 95:568-578.
27. Alvarez-Guardia D., Palomer X., Coll T., et al. PPARbeta/delta activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochim. Biophys. Acta 2011, 1811:59-67.
28. Berger J., Moller D.E. The mechanisms of action of PPARs. Ann. Rev. Med. 2002, 53:409-435.
29. Vega R.B., Huss J.M., Kelly D.P. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell Biol. 2000, 20:1868-1876.
30. Sato O., Kuriki C., Fukui Y., Motojima K. Dual promoter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional activation by peroxisome proliferator-activated receptor alpha and gamma ligands. J. Biol. Chem. 2002, 277:15703-15711.
31. Glosli H., Gudbrandsen O.A., Mullen A.J., et al. Down-regulated expression of PPARalpha target genes, reduced fatty acid oxidation and altered fatty acid composition in the liver of mice transgenic for hTNFalpha. Biochim. Biophys. Acta 2005, 1734:235-246.
32. Sarma S., Ardehali H., Gheorghiade M. Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure. Heart Fail Rev. 2010.
33. Zhou Y.T., Grayburn P., Karim A., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl. Acad. Sci. USA 2000, 97:1784-1789.
34. Aasum E., Belke D.D., Severson D.L., et al. Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H949-H957.
35. Finck B.N., Lehman J.J., Leone T.C., et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 2002, 109:121-130.
36. Finck B.N., Han X., Courtois M., et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl. Acad. Sci. USA 2003, 100:1226-1231.
37. Watanabe K., Fujii H., Takahashi T., et al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J. Biol. Chem. 2000, 275:22293-22299.
38. Peters J.M., Hennuyer N., Staels B., et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J. Biol. Chem. 1997, 272:27307-27312.
39. Campbell F.M., Kozak R., Wagner A., et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J. Biol. Chem. 2002, 277:4098-4103.
40. Cheng L., Ding G., Qin Q., et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 2004, 10:1245-1250.
41. Ouwens D.M., Diamant M., Fodor M., et al. Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification. Diabetologia 2007, 50:1938-1948.
42. Carley A.N., Atkinson L.L., Bonen A., et al. Mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db/db mice. Arch. Physiol. Biochem. 2007, 113:65-75.
43. Bonen A., Parolin M.L., Steinberg G.R., et al. Triacylglycerol accumulation in human obesity and type 2 diabetes is associated with increased rates of skeletal muscle fatty acid transport and increased sarcolemmal FAT/CD36. Faseb J. 2004, 18:1144-1146.
44. Kalinowska A., Gorski J., Harasim E., Harasiuk D., Bonen A., Chabowski A. Differential effects of chronic, in vivo, PPAR's stimulation on the myocardial subcellular redistribution of FAT/CD36 and FABPpm. FEBS Lett. 2009, 583:2527-2534.
45. Cresser J., Bonen A., Chabowski A., et al. Oral administration of a PPAR-delta agonist to rodents worsens, not improves, maximal insulin-stimulated glucose transport in skeletal muscle of different fibers. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 299:R470-R479.
46. Choi K., Kim Y.B. Molecular mechanism of insulin resistance in obesity and type 2 diabetes. Korean J. Intern. Med. 2010, 25:119-129.
47. Van Obberghen E., Baron V., Delahaye L., et al. Surfing the insulin signaling web. Eur. J. Clin. Invest. 2001, 31:966-977.
48. Stump C.S., Henriksen E.J., Wei Y., Sowers J.R. The metabolic syndrome: role of skeletal muscle metabolism. Ann. Med. 2006, 38:389-402.
49. Cho J.Y., Park J. Contribution of natural inhibitors to the understanding of the PI3K/PDK1/PKB pathway in the insulin-mediated intracellular signaling cascade. Int. J. Mol. Sci. 2008, 9:2217-2230.
50. Sharma N., Arias E.B., Sajan M.P., et al. Insulin resistance for glucose uptake and Akt2 phosphorylation in the soleus, but not epitrochlearis, muscles of old vs. adult rats. J. Appl. Physiol. 2010, 108:1631-1640.
51. Park S., Komatsu T., Hayashi H., et al. Calorie restriction initiated at a young age activates the Akt/PKC zeta/lambda-Glut4 pathway in rat white adipose tissue in an insulin-independent manner. Age (Dordrecht) 2008, 30:293-302.
52. Luiken J.J., Ouwens D.M., Habets D.D., et al. Permissive action of protein kinase C-zeta in insulin-induced CD36- and GLUT4 translocation in cardiac myocytes. J. Endocrinol. 2009, 201:199-209.
53. Braiman L., Alt A., Kuroki T., et al. Activation of protein kinase C zeta induces serine phosphorylation of VAMP2 in the GLUT4 compartment and increases glucose transport in skeletal muscle. Mol. Cell Biol. 2001, 21:7852-7861.
54. Goldberg I.J., Eckel R.H., Abumrad N.A. Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways. J. Lipid Res. 2009, 50:S86-S90.
55. Schwenk R.W., Luiken J.J., Bonen A., Glatz J.F. Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. Cardiovasc. Res. 2008, 79:249-258.
56. Boudina S., Bugger H., Sena S., et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 2009, 119:1272-1283.
57. Cho H., Mu J., Kim J.K., et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001, 292:1728-1731.
58. Mora A., Davies A.M., Bertrand L., et al. Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. Embo J. 2003, 22:4666-4676.
59. Luo J., McMullen J.R., Sobkiw C.L., et al. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol. Cell Biol. 2005, 25:9491-9502.
60. Doehner W., Rauchhaus M., Ponikowski P., et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J. Am. Coll. Cardiol. 2005, 46:1019-1026.
61. Dinh W., Futh R., Lankisch M., et al. Cardiovascular autonomic neuropathy contributes to left ventricular diastolic dysfunction in subjects with type 2 diabetes and impaired glucose tolerance undergoing coronary angiography. Diabet. Med. 2010.
62. Stahrenberg R., Edelmann F., Mende M., et al. Association of glucose metabolism with diastolic function along the diabetic continuum. Diabetologia 2010, 53:1331-1340.
63. Coort S.L., Bonen A., van der Vusse G.J., Glatz J.F., Luiken J.J. Cardiac substrate uptake and metabolism in obesity and type-2 diabetes: role of sarcolemmal substrate transporters. Mol. Cell Biochem. 2007, 299:5-18.
64. Yu C., Chen Y., Cline G.W., et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 2002, 277:50230-50236.
65. Schenk S., Saberi M., Olefsky J.M. Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 2008, 118:2992-3002.
66. Stratford S., DeWald D.B., Summers S.A. Ceramide dissociates 3'-phosphoinositide production from pleckstrin homology domain translocation. Biochem. J. 2001, 354:359-368.
67. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 1990, 322:1561-1566.
68. Efe J.A., Hilcove S., Kim J., et al. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat. Cell Biol. 2011.
69. Yi B.A., Wernet O., Chien K.R. Pregenerative medicine: developmental paradigms in the biology of cardiovascular regeneration. J. Clin. Invest. 2010, 120:20-28.
70. Barry S.P., Townsend P.A. What causes a broken heart--molecular insights into heart failure. Int. Rev. Cell Mol. Biol. 2010, 284:113-179.
71. Grossman W., Jones D., McLaurin L.P. Wall stress and patterns of hypertrophy in the human left ventricle. J. Clin. Invest. 1975, 56:56-64.
72. Opie L.H., Commerford P.J., Gersh B.J., Pfeffer M.A. Controversies in ventricular remodelling. Lancet 2006, 367:356-367.
73. Murarka S., Movahed M.R. Diabetic cardiomyopathy. J. Card. Fail 2010, 16:971-979.
74. Boyer J.K., Thanigaraj S., Schechtman K.B., Perez J.E. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am. J. Cardiol. 2004, 93:870-875.
75. Zabalgoitia M., Ismaeil M.F., Anderson L., Maklady F.A. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am. J. Cardiol. 2001, 87:320-323.
76. Nikolaidis L.A., Levine T.B. Peroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure?. Cardiol. Rev. 2004, 12:158-170.
77. Barouch L.A., Berkowitz D.E., Harrison R.W., O'Donnell C.P., Hare J.M. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003, 108:754-759.
78. Yang J., Sambandam N., Han X., et al. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ. Res. 2007, 100:1208-1217.
79. Glenn D.J., Wang F., Nishimoto M., et al. A murine model of isolated cardiac steatosis leads to cardiomyopathy. Hypertension 2011, 57:216-222.
80. Condorelli G., Drusco A., Stassi G., et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc. Natl. Acad. Sci. USA 2002, 99:12333-12338.
81. Shioi T., McMullen J.R., Kang P.M., et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell Biol. 2002, 22:2799-2809.
82. Fang C.X., Dong F., Thomas D.P., Ma H., He L., Ren J. Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H1206-H1215.
83. Shiomi T., Tsutsui H., Ikeuchi M., et al. Streptozotocin-induced hyperglycemia exacerbates left ventricular remodeling and failure after experimental myocardial infarction. J. Am. Coll. Cardiol. 2003, 42:165-172.
84. Fischer V.W., Barner H.B., Larose L.S. Pathomorphologic aspects of muscular tissue in diabetes mellitus. Hum. Pathol. 1984, 15:1127-1136.
85. Martinez D.A., Guhl D.J., Stanley W.C., Vailas A.C. Extracellular matrix maturation in the left ventricle of normal and diabetic swine. Diabetes Res. Clin. Pract. 2003, 59:1-9.
86. Hirotani S., Otsu K., Nishida K., et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002, 105:509-515.
87. Nishida M., Maruyama Y., Tanaka R., Kontani K., Nagao T., Kurose H. G alpha(i) and G alpha(o) are target proteins of reactive oxygen species. Nature 2000, 408:492-495.
88. Molkentin J.D. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc. Res. 2004, 63:467-475.
89. Kandasamy A.D., Chow A.K., Ali M.A., Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc. Res. 2010, 85:413-423.
90. Goser S., Andrassy M., Buss S.J., et al. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation 2006, 114:1693-1702.
91. Tsutsui H., Kinugawa S., Matsushima S. Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc. Res. 2009, 81:449-456.
92. Chen L., Knowlton A.A. Mitochondria and heart failure: new insights into an energetic problem. Minerva Cardioangiol. 2010, 58:213-229.
93. Li C.J., Zhang Q.M., Li M.Z., Zhang J.Y., Yu P., Yu D.M. Attenuation of myocardial apoptosis by alpha-lipoic acid through suppression of mitochondrial oxidative stress to reduce diabetic cardiomyopathy. Chin. Med. J. (Engl.) 2009, 122:2580-2586.
94. Cai L., Li W., Wang G., Guo L., Jiang Y., Kang Y.J. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 2002, 51:1938-1948.